Introduction
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with an extremely variable course; survival after diagnosis can range from months to decades. 1 As a result, treatment must be flexible and tailored for different patient groups. With a rapidly growing knowledge of the disease and its associated prognostic and treatment response factors, the treatment choices have evolved.
This review presents an overview of our current understanding in this exciting and rapidly changing field, in which recent developments focus on the benefit of chemoimmunotherapy, the most effective treatment combinations and the potential importance of depth and duration of response.
Diagnostic parameters, prognostic markers and treatment and response guidelines
Progress in understanding diagnostic parameters, prognostic markers and treatment guidelines are beyond the scope of this article, but have recently been reviewed. [2] [3] [4] (Tables 1-3) .
Cytogenetic tests are now recommended before initiation of therapy because patients with a del(17p) have a poor outcome after conventional chemoimmunotherapy and should be managed differently (see section below Selection based on likely progression rate). Assessment of immunoglobulin heavy chain variable region genes mutational status and ZAP-70/CD38 expression is advised for incorporation into clinical trials and for patients who are interested in expected outcomes. The new guidelines recommend using flow cytometry and CT scanning for a more accurate assessment of response to therapy in clinical trials, but not in general practice. These parameters were not included in the 1996 National Cancer Institute-sponsored Working Group Guidelines for CLL. 5 Table 4 outlines the updated response definitions from the International Workshop on CLL (IWCLL). 2 
Evolution of the current standard of care

Single-agent chemotherapy
Monotherapy with chlorambucil or cyclophosphamide, both alkylating agents, has served as initial, front-line therapy for CLL for several decades and these are still considered appropriate by many specialists, particularly in a frail or medically unfit (with comorbidities) patient. The advantages of single-agent chlorambucil or cyclophosphamide are related to their toxicity profiles, low cost and convenience in use, however, they are associated with a very low complete response (CR) rate; myelodysplasia and secondary acute leukemia may be seen with extended use. 6 In the 1980s, the introduction of purine analogs, particularly fludarabine, changed the front-line treatment paradigm for CLL. Compared with chlorambucil, fludarabine gave improved overall response rates (ORRs) (Po0.001) and progression-free survival (PFS) (Po0.001), but did not show an improvement in overall survival (OS) ( Table 5) . 7 Many of the patients in the chlorambucil arm in this study were crossed over to fludarabine and responded, while the fludarabine recipients crossed over to chlorambucil rarely responded. It is possible that this had an effect on the OS data and as a consequence, final data underestimated the impact of fludarabine on OS. Results were similar when fludarabine was compared with other alkylator combination regimens such as CAP 8 (cyclophosphamide, doxorubicin and prednisone) and CHOP 9 (cyclophosphamide, doxorubicin, vincristine and prednisone) ( Table 5 ). In elderly patients, fludarabine also led to improved responses versus chlorambucil; ORRs and CRs were significantly higher for fludarabine (Po0.001 and Po0.008, respectively); however, PFS and OS were not significantly different, suggesting the treatments gave similar efficacy in this study. 10 Cladribine, a similar purine analog to fludarabine, when combined with prednisone gave improved CR rates and ORRs compared with chlorambucil and prednisone (47 versus 12 and 87 versus 57%, respectively; P ¼ 0.001) with improved PFS (P ¼ 0.01) without improved OS. 11 In a preliminary report of a large randomized study, cladribine monotherapy also compared favorably to fludarabine monotherapy with ORRs of 62% for chlorambucil (n ¼ 76), 70% for fludarabine (n ¼ 73) and 75% for cladribine (n ¼ 72), (NS). 12 Pentostatin also appears to have activity in CLL; a phase 2 study of pentostatin monotherapy in 39 previously treated CLL patients gave an ORR of 26% and 3% CRs. 13 In addition, single-agent bendamustine has shown improved responses when compared with chlorambucil.
14 Bendamustine is a novel alkylator with a mechanism of action that differentiates it from standard alkylating agents. 15 The ORRs and median PFS in this large study of 319 patients were 68% and 22 months, respectively, for bendamustine versus 31% and 8 months for chlorambucil (both Po0.0001). CRs were reported in 31% of bendamustine recipients versus 2% with chlorambucil. Grade 3/4 neutropenia occurred in 43% of patients treated with bendamustine and 21% of those receiving chlorambucil. Bendamustine has been approved by the US FDA for the treatment of CLL.
Combining purine analogs with alkylating agents
The unique mode of action of purine analogs makes them suitable for combining with other drugs. Preclinical in vitro studies showed that exposure of CLL cells to fludarabine and cyclophosphamide (FC) together resulted in synergistic cytotoxicity. 16, 17 Phase 2 trials showed that combining purine analogs (fludarabine, cladrabine and pentostatin) with cyclophosphamide leads to excellent clinical responses. [18] [19] [20] [21] Three randomized trials in untreated patients comparing FC versus fludarabine monotherapy (Table 6) , [22] [23] [24] showed superior CRs, ORRs and PFS for the FC arm although OS was not improved. However, a recent analysis of the subgroup of patients without high-risk genetic deletions in the CLL4 trial of the German Chronic Lymphocytic Leukemia Study Group showed that FC did prolong the OS in these patients when compared with fludarabine monotherapy. 25 One trial of cladribine (C) versus cladribine and cyclophosphamide (CC) versus cladribine, cyclphosphamide plus mitoxantrone 26 showed superior CRs for the cyclphosphamide plus mitoxantrone arm over C but not the CC arm (Table 6 ).
Monoclonal antibodies
The monoclonal antibody rituximab targets the CD20 antigen and has been the mainstay of treatment for CD20-positive lymphoma since 1997. The benefits of chemoimmunotherapy with rituximab have been significant in patients with nonHodgkin's lymphoma. 27, 28 Initial studies with rituximab monotherapy in previously treated patients with CLL and small lymphocytic lymphoma showed ORRs of 10-15%, [29] [30] [31] [32] and although responses may be seen in up to 50% of untreated patients they are usually transient and CRs are rare. 33 The primary toxicities with rituximab are infusional reactions. Other side effects such as tumor lysis syndrome, reactivation of hepatitis, neutropenia, severe mucocutaneous reactions and progressive multifocal leukoencephalopathy are rare, but may be fatal. Explanation of the poor response rate in CLL and small lymphocytic lymphoma include low density of CD20 antigen on the tumor cells and altered pharmacokinetics because of the high intravascular tumor volume. Two studies suggested that ORR to rituximab monotherapy in previously treated CLL patients may be dose dependent but responses in these studies were transient and limited to partial responses (PRs). 34, 35 In contrast, a pilot study suggested that even at a very low dose of rituximab (60 mg/m 2 thrice weekly) there may be CD20 epitope loss to o20% and subsequent infusions of rituximab are /l or 450% improvement over baseline a CR ¼ complete remission, all criteria must be met without disease-related constitutional symptoms; PR ¼ partial response, at least two of Group A criteria and one Group B criteria; PD ¼ progressive disease, at least one criteria of Group A or B must be met.
b Sum of products of multiple lymph nodes (by CT scans in clinical trials and physical examination in general practice). c In clinical trials, the presence of minimal residual disease should be assessed and the sensitivity of the method used to evaluate MRD should be reported (for example, routine flow cytometry or immunohistochemistry have 1% sensitivity; 4 color flow cytometry and allele-specific oligonucleotide PCR have 0.01% sensitivity). CRi; incomplete complete response for patients who fulfil the criteria for CR with persistent anemia, thrombocytopenia, or neutropenia likely related to drug toxicity. Table 5 Phase 3 trials of fludarabine monotherapy in untreated CLL patients Abbreviations: CAP, cyclophosphamide, doxorubicin, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; OR, overall response; OS, overall survival; PFS, progression-free survival. ineffective, whereas lower dose (20 mg/m 2 thrice weekly) has X50% epitope retention and better clearance of leukemia cells with subsequent rituximab infusions. 36 These interesting and provocative data warrant further investigation.
Monotherapy with alemtuzumab, a recombinant monoclonal antibody that targets the CD52 cell-surface antigen, has efficacy in previously treated patients and untreated patients and has been approved by the US FDA for both indications. In one study, 91 previously treated CLL patients received 30 mg alemtuzumab 3 times per week for a median of 9 weeks 37 resulting in a CR rate of 36%, a PR rate of 19% with 46% showing no response. Using 4-color flow cytometry for minimal residual disease (MRD), 20% of patients were negative for MRD. Patients achieving an MRD-negative CR had a longer treatment-free survival than those with MRD-positive CRs, PRs or non responses (median treatment-free survival not reached versus 20 months, 13 and 6 months, respectively; Po0.0001). OS for the 18 patients with MRD-negative remissions was 84% at 60 months. In another study, 93 relapsed/refractory CLL patients received 30 mg alemtuzumab for a maximum of 12 weeks. 38 Overall response was 33% (CR ¼ 2%; PR ¼ 31%) and median time to progression (TTP) was 4.7 months overall and 9.5 months for responders. Grade 3/4 infections were observed in 27% of patients.
The pivotal front-line study for alemtuzumab randomized 297 untreated patients to receive alemtuzumab 30 mg three times a week or chlorambucil 40 mg/m 2 every 28 days, for up to 12 months. 39 Results showed alemtuzumab was associated with a significantly superior PFS, with a 42% reduction in risk of progression or death compared with chlorambucil (P ¼ 0.001), and a median time to alternative treatment of 23.3 months for alemtuzumab versus 14.7 months for chlorambucil (P ¼ 0.001). Alemtuzumab recipients had an ORR of 83% (CR ¼ 24%) compared with 55% (CR ¼ 20%) for chlorambucil; a highly significant difference (Po0.0001). Elimination of MRD occurred in 11 of 36 complete responders treated with alemtuzumab versus none with chlorambucil. Adverse events were similar except that alemtuzumab was associated with more infusionrelated events and more reactivations of cytomegalovirus and chlorambucil was associated with more nausea and vomiting. Cytomegalovirus-associated events did not impact the efficacy with alemtuzumab.
Chemoimmunotherapy: the next step in the evolving treatment paradigm
Combining cytostatic agents with monoclonal antibodies produced a major improvement in management strategies for CLL. The rationale for the move came from compelling pre-clinical evidence of synergism between rituximab and chemotherapeutic agents [40] [41] [42] [43] and from the success of chemoimmunotherapy in follicular and diffuse large B-cell lymphoma. 27, 28, 44, 45 Owing to the minimal overlap of toxicity of the modalities any enhanced efficacy was not predicted to occur at the expense of tolerability.
Rituximab and fludarabine
The first studies of rituximab combined with fludarabine (FR) gave encouraging results. 46, 47 In a randomized phase 2 study fludarabine with concurrent rituximab (n ¼ 51) was compared to fludarabine with sequential rituximab (n ¼ 53) in untreated patients with CLL. 48 The ORR with the concurrent regimen was 90% (47% CRs and 43% PRs) compared with 77% in the sequential arm (28% CRs and 49% PRs). The authors concluded that future phase 3 trials should focus on the combined regimen. The results of this study were also compared retrospectively with an earlier trial of 178 previously untreated patients with CLL treated with fludarabine monotherapy; 7 2-year PFS probabilities were 67% for FR versus 45% for fludarabine alone (Po0.0001). There was a potential survival advantage with combined treatment as the OS probability was 93% for FR versus 81% for fludarabine alone (P ¼ 0.0006). 49 
Alemtuzumab and fludarabine
Alemtuzumab in combination with chemotherapy has also shown good responses in relapsed/refractory disease; a phase 2 study in 36 patients treated with 30 mg alemtuzumab plus fludarabine 30 mg/m 2 for 3 consecutive days every 28 days 50 gave an ORR of 83% with a CR rate of 31%. A median TTP of 13.0 months was reported for the entire patient cohort; for patients who achieved a CR, median TTP was 21.9 months. Two patients developed fungal pneumonia and one died of Escherichia coli sepsis.
Fludarabine, cyclophosphamide and rituximab (FCR) þ /À additional agents
As combination chemotherapy with FC had already shown benefits over fludarabine alone, it was rational for investigators to consider adding rituximab to this combination chemotherapy. The FCR regimen includes fludarabine 25 mg/m 2 on days 2-4 during the first cycle and days 1-3 for the subsequent five cycles, cyclophosphamide at 250 mg/m 2 (same schedule as fludarabine) and rituximab on day 1 of the first cycle at 375 mg/m 2 and on day 1 of the next 5 cycles at 500 mg/m 2 .
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Rituximab is administered before chemotherapy. In the initial phase 2 trial of FCR in 224 patients with progressive or advanced untreated CLL, results showed an ORR of 95%, a CR rate of 70%, a nodular PR (nPR) rate of 10% and a PR rate of 15% (updated data is presented in Table 7 ). 51, 52 Two-thirds of patients had no detectable MRD as assessed by flow cytometry, and 69% were projected to be failure free at 4 years. Grade 3/4 neutropenia occurred in 52% of courses. Long-term results for these patients at a median follow-up of 6 years showed overall and failure-free survival rates of 77 and 51%, respectively. 52 Median TTP was 80 months.
In another phase 2 trial 177 relapsed/refractory patients were treated with FCR. 53 The median number of previous therapies was 2 (range 1-10). Results showed a CR rate of 25%, an nPR rate of 16% and a PR rate of 32%. Median TTP was 28 months for all patients and was 39 months for complete responders. The overall median survival was 42 months for all patients and was 445 months for complete responders.
In another study, 36 treatment-naive patients received a sequential treatment regimen with fludarabine 25 mg/m 2 days 1-5 every 4 weeks for six cycles, followed by consolidation with 3 g/m 2 of cyclophosphamide every 3 weeks for three cycles, then weekly rituximab 375 mg/m 2 for four cycles. 54 This regimen led to 89% ORs with 61% CRs. Consolidation with cyclophosphamide-improved responses in 36% of patients and 25% further improved their responses with rituximab. Fifty-six percent of patients achieved flow cytometry CR and 33% achieved molecular CR. Grade 3/4 neutropenia was reported in 89% of patients, grade 3/4 thrombocytopenia in 78% and grade 3/4 infections occurred in 14%.
The FCR-Lite regimen was designed to maintain the efficacy of FCR with reduced grade 3/4 neutropenia. 55 In this regimen, fludarabine was reduced to 20 mg/m 2 days 2-4 during cycle 1
and days 1-3 in cycle 2-5, cyclophosphamide was reduced to 150 mg/m 2 (same schedule as fludarabine) and rituximab was given on day 1 of cycle 1 at a dose of 375 mg/m 2 and on cycles 2-5 on day 1 at 500 mg/m 2 preceding chemotherapy and on day 14 of each cycle. Maintenance rituximab at 500 mg/m 2 was given every 3 months until progression. The CR rate was 79% for 50 previously untreated CLL patients with an ORR of 100%. At a median follow-up of 2.4 years all complete responders remain in CR except for one patient who died of a myocardial infarction while still in remission. Grade 3/4 neutropenia was documented in only 13% of cycles, considerably less than reported with the standard FCR regimen (52% of cycles). 51 Preliminary results are now available for two large phase 3 prospective randomized studies of FCR versus FC (Table 8) . 56, 57 As front-line treatment, ORR and CR rates were significantly superior for FCR (95 versus 88%, Po0.001 and 52 versus 27%, Po0.0001, respectively), as was PFS at 2 years (77 versus 62%, Po0.0001).
56 Grade 3/4 neutropenia was seen in 34% of patients treated with FCR versus 21% treated with FC (P ¼ 0.0001); however, this was not associated with an increase in grade 3/4 infections. The second study (REACH) was an open-label, randomized trial in relapsed or refractory patients. 57 Again, the ORR, CR and PFS were significantly better for FCR. Grade 3/4 neutropenia and febrile neutropenia were marginally increased for FCR (42 and 15%) versus FC (40 and 12%, respectively) but grade 3/4 infections were similar.
Some investigators have studied the effect of adding agents to FCR. In one study of 72 previously untreated patients, mitoxantrone at 6 mg/m 2 was added to FCR on day 1 of each cycle (R-FCM) with an ORR of 93%, an MRD-negative CR rate of 46%, an MRD-positive CR rate of 36% and a PR rate of 10%. 58 Major infections were reported in 8% of cycles. In another study, 30 previously untreated patients received FCR with 6 mg/m 2 of mitoxantrone (FCM-R) on day 2 of each cycle. 59 CRs were reported in 83%, nPR in 10% and PR in 3%. Median TTF was not reached at 38.5 months but investigators concluded that the outcome was similar to FCR. Forty-eight previously untreated patients with high-risk CLL (including patients with del(17p)), 60 were treated with FCR plus alemtuzumab (CFAR) with an ORR of 94% and CR of 69% of patients. They reported greater MRD eradication compared with previous FCR studies, but this came at the expense of greater myelosuppression.
Other rituximab combinations
Thirty-two previously treated patients received pentostatin 4 mg/m 2 , cyclophosphamide 600 mg/m 2 and rituximab 375 mg/m 2 every 3 weeks for 6 cycles. 61 With this combination there was a 75% ORR and 25% CR rate and 72% of patients received planned treatment at full dose. In another trial, 64 untreated patients with high Rai risk or other high-risk biological features (for example, 17% had unmutated immunoglobulin heavy chain), received pentostatin 2 mg/m 2 on day 1, cyclophosphamide 600 mg/m 2 on day 1 and rituximab 375 mg/m 2 on day 1, every 21 days for 6 cycles. 62 Grade 3/4 hematological toxicity was seen in 58% of patients and grade 3/4 neutropenia was seen in 16% of cycles as compared with 52% with FCR and 13% with FCR-lite. The ORR was 91%, with a CR rate of 41%, an nPR rate of 22% and a PR rate of 28%. This regimen was equally effective in young versus older (470 years) patients. In a subsequent study, 63 cyclophosphamide was shown to be an important component of the regimen.
A preliminary report of a community-based, randomized trial of FCR versus PCR in previously untreated and minimally treated CLL patients showed no statistical differences between the two treatments in OS or response. 64 Infection rate (fever 4101 1F requiring antibiotics) was the primary end point of this study and also showed no significant difference between the two arms (31% in FCR and 34% in PCR). This study included previously treated patients and pentostatin was given at 4 mg/m 2 rather Forty-six refractory or relapsed CLL patients were treated with cladribine plus rituximab (RC) with or without cyclophosphamide (RCC). 65 ORR was 67% in 12 patients treated with RC and 78% in 22 treated with RCC. Grade 3/4 neutropenia was seen in 13%, grade 3/4 thrombocytopenia in 9% and grade 3/4 infections in 28% of patients. Other groups have studied rituximab in combination with alemtuzumab, 66 bendamustine, 67 and high-dose methylprednisone. 68 
Impact on survival
In the staging systems originally reported by Rai 69 and Binet 70 the median survival of Rai stage III and IV and Binet stage C was p2 years. In a report from the Mayo Clinic median survival for patients with Rai stage III and IV (cytopenia secondary to bone marrow failure) from 1995-2004 was 4.4 years. 71 Importantly, median survival for autoimmune cytopenia, which represented 25% of the total cases was 9.1 years. Many of these patients would have been included in the original data where the median survival was o2 years, as the Rai and Binet staging systems did not distinguish bone marrow failure from autoimmune cytopenia. 69, 70 In another report from Barcelona, survival in CLL patients at 5 and 10 years was significantly improved from 1995 to 2004 as compared with 1980 to 1994. 72 The improved survival was largely because of a decrease in CLL-related mortality in patients o70 years and patients with Binet stage B or C. These data suggest that newer therapies and possibly improved supportive care are changing the prognosis of younger patients with advanced disease. A population-based study of CLL patients demonstrated that 5 and 10-year absolute survival from diagnosis comparing cohorts from 1980-1984 and 2000-2004 increased from 54% to 60% (Po0.0001) and 28% to 35% (Po0.0001), respectively. 73 In summary, these studies suggest that improved therapies, particularly in younger patients, might have a positive impact on overall survival.
Pragmatism and tailored care
There are many treatment options and many regimens currently under investigation, however, to date, none can be considered the 'standard' of care for all patients. Outside of a clinical research protocol, treatment should follow established guidelines.
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Based on patient characteristics Selection of the most appropriate initial therapy in CLL must be based primarily on patient characteristics such as age and performance status. These factors help practitioners to define the goal of therapy and therefore the acceptable ratio of efficacy to toxicity. Comorbidities can also pose specific restrictions on treatment choice. As discussed above, data suggests that improved therapies are leading to improved overall survival, particularly in high clinical stage younger patients. 72 Data also suggests that obtaining MRD-negative complete response improves survival. 37 Therefore, if our goal is MRD-negative complete responses, what is the current optimal therapy? In drawing this conclusion we are limited by the lack of phase 3 data comparing the most popular regimens. We have phase 2 data introducing promising new agents and combinations and limited phase 3 data comparing popular regimens. In summary, purine nucleosides have a higher CR rate than alkylating agents. 7, 10, 12 Combining a purine nucleoside with an alkylating agent such as cyclophosphamide gives superior responses to single-agent purine nucleosides. [22] [23] [24] Phase 3 data in untreated and treated patients showed that FCR has superior responses to FC 56, 57 and long-term FCR data reports CRs lasting a median of 47 years. 75 Based on these data, we recommend FCR as the optimal treatment for patients who are candidates for this chemoimmunotherapy when the goal of therapy is to obtain a complete remission (Table 9) .
What has not been answered in a randomized fashion is whether FCR is superior to FR, PCR, CCR, FCR-Lite, BR, alemtuzumab and other regimens. Phase 2 data suggests that adding additional agents such as mitoxantrone to FCR does not increase efficacy. [58] [59] [60] If BR, PCR or FCR-Lite have equal efficacy and less toxicity than FCR then they might be preferable front-line treatments; however, currently there is no phase 3 data to support this. Phase 2 data suggests that both FCR-Lite 55 and PCR 59 have considerably less grade 3/4 neutropenia than FCR.
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Alemtuzumab is also a very effective front-line monotherapy but did not appear to improve the efficacy when combined with FCR 60 and major toxicities were reported when it was used for consolidation therapy. 76, 77 Alternatively, if control of symptoms is the essential treatment goal for unfit CLL patients, a regimen with a favorable tolerability profile should be applied. As the elderly, medically unfit are often excluded from clinical trials by design or circumstance, the evidence base for this group is limited. There exists numerous therapies for patients who are not candidates for FCR or other chemoimmunotherapies. Chlorambucil does not lead to CRs but is palliative and is still quite popular, particularly outside of the United States. Alemtuzumab and bendamustine are approved as front-line therapies based on superior responses to chlorambucil. Single-agent purine nucleosides have superior response to chlorambucil and are also an option. Single-agent rituximab, rituximab plus alemtuzumab and high-dose prednisone plus rituximab should only be given in the research setting.
Selection based on likely progression rate
Treatment selection must also take into consideration the patient's disease burden and anticipated progression rate. If early intervention for those predicted to have aggressive disease becomes the standard, selection of the most appropriate firstline regimen will become crucial, as treatment of relapsed CLL is often less effective. To date there are no data to prove that early intervention impacts outcome, although currently the German Chronic Lymphocytic Leukemia Study Group (CLL7) and the Cancer and Leukemia Group B (CALBG, C10501) are investigating the role of early intervention versus deferred treatment with FCR (CLL7) or FR (C10501) in patients with high-risk disease based on prognostic markers but who do not meet the iwCLL criteria for treatment intervention.
Alemtuzumab may be appropriate for patients with genetic markers that correlate with poor prognosis (for example, del(17p)), potentially achieving MRD and prolonging survival. 37 In a phase 2 trial with 36 patients, alemtuzumab proved effective in fludarabine-refractory CLL, even in those with p53 mutations or deletions including 17p deletion. 78 Combination monoclonal antibodies could also be a potential early treatment for high-risk patients. One study investigated the effects of alemtuzumab plus rituximab in patients who were not candidates for treatment by standard IWCLL or NCCN criteria but had at least one high-risk biological feature (for example, del(17p); del(11q); unmutated IGVH (o2%) and expression of ZAP-70 (X30%) and/or CD38 (X20%)). 79 Treatment led to an ORR of 93%, a CR rate of 44% and minimal toxicity. Whether such therapy will have an impact on survival is not clear and remains to be shown in prospective studies.
Hematopoietic stem cell transplantation (HSCT)
Stem cell transplant is beyond the scope of this article and has been recently reviewed. [80] [81] [82] Allogeneic HSCT has curative potential and non-myeloablative regimens may be more attractive in this older patient population. Unfortunately, many patients are evaluated too late in their course for HSCT. Patients who are refractory to nucleosides or who have del(17p) should be considered for allogeneic HSCT.
What next? Emerging trends
The range of treatment options for CLL has increased dramatically over the past decade, and numerous novel agents and combinations are currently being investigated. New intervention strategies are also being evaluated.
Potential new treatments
Monoclonal antibodies including lumiliximab (anti-CD23) 83 and ofatumumab 84 (anti-CD20) have shown activity in relapsed or refractory CLL and are likely to be investigated as components of chemoimmunotherapy or in combination with other monoclonal antibodies. Ofatumumab has been approved by the US FDA for the treatment of CLL patients who have failed fludarabine and alemtuzumab.
Lenalidomide is an immunomodulating drug with anti-tumor activity. It has been studied in small phase 2 trials in untreated and in relapsed/refractory CLL where it has shown activity, although further work is required to establish an appropriate dose because myelosuppression and tumor flare can be problematic. [85] [86] [87] [88] [89] Flavopiridol is a broad cyclin-dependent kinase inhibitor 90, 91 that induces apoptosis in CLL cells in vitro. 92, 93 Flavopiridol induced viable responses in relapsed, high-risk CLL patients 94 but has been associated with hyperacute tumor lysis syndrome. 95 Oblimersen, a synthetic Bcl-2 antisense oligonucleotide, has been shown to prolong the response duration and survival in those patients that responded to treatment in a phase III trial, in patients with relapsed/ refractory CLL. Expression of the anti-apoptotic protein Bcl-2 is associated with the pathogenesis of CLL. 96 Oblimersen has a single-agent activity against CLL cells 97 and potentiates the cytotoxic activity of fludarabine, alemtuzumab and rituximab. 98, 99 It has been associated with thrombocytopenia and, rarely, tumor lysis syndrome and cytokine release reactions. 100, 101 A completely different approach to CLL management may be to develop vaccines that induce cell-mediated host immune responses against CLL cells. However, candidates are still only in phase 1 development. A variety of approaches have been used including autologous leukemia cells or dendritic cells pulsed with tumor-associated antigen. 102 Early results show that the vaccines may stimulate an increase in T cells, reduce leukemia cell counts and reduce the size of lymph nodes and spleen. [103] [104] [105] New approaches Adjusting the number of cycles of chemoimmunotherapy. One issue that has not been addressed is the optimum number of cycles of chemoimmunotherapy in the setting where we want to maximize complete responses. The typical regimen is six cycles of therapy. If none of the Table 9 Proposal of an algorithm for front-and second-line tailored therapy 107 In all of these series, MRD-negative patients survive longer than MRDpositive patients.
Rituximab has been studied as a post-induction treatment. In one study, rituximab monotherapy was given as a consolidation therapy at 6 monthly intervals in those responding to or stable after initial front-line rituximab monotherapy for 4 weeks; 33 consolidation promoted additional responses, increasing the ORR and CR rate from 51 and 4%, respectively, after initial therapy to 58 and 9% after consolidation. The median PFS was 18.6 months at the time of reporting, with 1-year and 2-year PFS projected to be 62 and 49% respectively. In a similar study, rituximab consolidation was evaluated in 28 patients showing CR or PR to 6 monthly cycles of fludarabine but retaining MRD. 108 Consolidation was initially given once a month for 4 months at doses of 375 mg/m 2 , followed by post-induction doses of rituximab of 150 mg/m 2 once a month for 12 months. Postinduction therapy significantly increased response duration compared with controls (87 versus 32% at 5 years, P ¼ 0.001). The use of rituximab in the post-induction setting should be limited to clinical trials.
Alemtuzumab monotherapy following chemotherapy for the eradication of MRD has also been studied. 109, 110 Results of a phase 3 trial by the German Chronic Lymphocytic Leukemia Study Group showed improved PFS with alemtuzumab consolidation therapy compared with the observation arm (no progression versus 24.7 months, P ¼ 0.036) when calculated from the start of fludarabine-based treatment. 111 In one study, 41 patients with MRD following chemotherapy were treated with alemtuzumab at 10 mg three times per week for 4 weeks. If they had residual disease they received an additional 4 weeks of therapy after a 4-week rest period. After the first 24 patients, all patients received 30 mg three times a week for 4 weeks. ORs were 46% with 11 of 29 (38%) achieving a molecular remission. 110 In another study, 44 patients p64 years who had a clinical response to a fludarabine-based induction regimen received alemtuzumab 10 mg subcutaneously three times per week for 6 weeks. CR rates improved from 35% after fludarabine induction to 79% after alemtuzumab consolidation including 56% who achieved MRD negativity. 109 Toxicity was considered acceptable in both studies, however, severe and lifethreatening toxicity has been reported in patients treated with alemtuzumab consolidation following induction with fludarabine and rituximab. 76, 77 The reasons for the disparate conclusions of these studies are not immediately obvious. Therefore, the use of of alemtuzumab in the post-induction setting should be limited to clinical trials.
Quantitative assessment of MRD in 471 patients in the CLL8 trial receiving FC or FCR has provided additional insight into the clinical significance of MRD. 112 Four-color flow cytometry showed that a low MRD was correlated with longer PFS regardless of treatment. The FCR regimen had lower median MRD compared with FC, resulting in longer PFS. Several clinical studies have also suggested that eradication of MRD may improve PFS, treatment-free survival and possibly OS. 37, 51, 62 MRD assessment is recommended by IWCLL in all clinical trials using either 4 color flow cytometry or allele-specific PCR (0.01% sensitivity), although evaluation of MRD is not recommended for routine clinical practice. 2 It remains unclear whether a survival advantage can be conferred by treating patients with CR who are MRD positive with post-induction therapy, rather than delaying treatment until disease progression. Furthermore, it is not known whether the benefits of eradicating MRD in this way may outweigh the risk of an extended period of immunosuppression, for example as with the severe infectious complications of alemtuzumab post-induction therapy. 76, 77 However, agents that may be less toxic than alemtuzumab can be considered in the MRD-positive setting. Larger randomized trials assessing the clinical significance of MRD are required before this end point can be applied to the clinical setting, and in addition, validated tests and certified laboratories are needed.
Conclusion
Treatment goals for CLL have evolved dramatically over the last decade. As with other indolent B-cell malignancies, we can now expect to see CRs with durable remission in nearly 50% of CLL patients treated with optimal chemoimmunotherapy regimens. Prognostic factors have evolved over the past 10 years that give us better foresight of the clinical course in individual patients and may help identify high-risk patients who may benefit from early intervention as well as identify optimal therapy for individual patients. Testing for MRD may also lead to tailored therapies for individual patients. With the rapidly changing paradigms in the therapy of CLL we now work toward improving the complete remissions, duration of remissions and survival in CLL patients and developing curative treatments.
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